Allurion Technologies Q1 Revenue Plunges 47%, EPS $(0.46) Misses Projections Amid Widening Loss
ALUR has more than doubled off its 52-week low of $0.23.
Summary
Allurion Technologies reported significantly weaker first-quarter 2026 results, with revenue plummeting 47% year-over-year to $2.95 million and a net loss widening to $6.1 million. The diluted EPS of $(0.46) was substantially worse than the $(0.34) loss per share projected by Reuters just a week prior, indicating a negative surprise for the market. These poor financial results exacerbate concerns for the micro-cap company, which already faces a 'going concern' warning and NYSE delisting, as noted in its last 10-K filing. While the company highlighted its recent FDA PMA approval for the Allurion Gastric Balloon System, the immediate financial deterioration overshadows this positive regulatory milestone. Traders will be watching for any further updates on the company's financial stability and the impact of its new B2B2C channel strategy.
At the time of this announcement, ALUR was trading at $0.85 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $0.23 to $3.33. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.